fingolimod has been researched along with gallocatechin-3-gallate in 1 studies
| Studies (fingolimod) | Trials (fingolimod) | Recent Studies (post-2010) (fingolimod) | Studies (gallocatechin-3-gallate) | Trials (gallocatechin-3-gallate) | Recent Studies (post-2010) (gallocatechin-3-gallate) |
|---|---|---|---|---|---|
| 65 | 0 | 51 | 90 | 0 | 52 |
| Protein | Taxonomy | fingolimod (IC50) | gallocatechin-3-gallate (IC50) |
|---|---|---|---|
| Beta-secretase 1 | Homo sapiens (human) | 1.8 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | 0.15 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Araldi, GL; Hwang, YW | 1 |
1 other study(ies) available for fingolimod and gallocatechin-3-gallate
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of polyphenol derivatives as DYRK1A inhibitors. The discovery of a potentially promising treatment for Multiple Sclerosis.
Topics: Catechin; Humans; Multiple Sclerosis; Phosphorylation; Polyphenols; Structure-Activity Relationship; Tea | 2022 |